A SMOLDERING / INDOLENT MYELOMA WITH EXTENSIVE ABDOMINAL
PRESENTATION- CASE REPORT.

C.E.Omoti,
Department of Haematology University of Benin Teaching Hospital P.M.B. 1111 Benin City

ABSTRACT
A case of indolent/smoldering myeloma in a 70-year-old man is reported. He presented with an unusual
multiple symptomatic myeloma with extramedullary impairment and absence of bone pain. He was treated with
pulses of high-dose dexamethasone with commendable clinical improvement.

Key words: Myeloma, Dexamethasone

INTRODUCTION
Plasma cell dyscrasias are a group of disorder that
arise from clonal proliferation of neoplastic plasma
cells or associated B cells. Typically clinical
manifestation varies as a result of the heterogenous
biology and span the entire spectrum from the early
phase of indolent/smoldering myeloma (SM) to highly
aggressive overt multiple myeloma (MM). Two
subsets of SM have been identified namely evolving
SM and non-evolving SM with stable M- paraprotein
that abruptly increases when symptomatic MM
develops. SM is characterized by M-protein >/= 30 /dl
and/or bone marrow clonal cells >/=10% but no
related organ or tissue impairment (ROT) (end-organ
damage) which is typically manifested by increased
calcium, renal insufficiency, anemia, or bone lesions
(CRAB) attributed to the plasma cell proliferative
process. A proportion of the patients have to be
followed up indefinitely for appropriate treatment to
avoid complications. This however is often difficult
in a developing country like ours where culture
attitude and follow up is a problem. This paper reports
the first case in 10 years in our institution of unusual
pattern of a myeloma case that was successfully
treated with high-dose of dexamethasone.

Case Report
A 70 year-old farmer was referred to the haematology clinic July 2004 with two-year history of
increasing abdominal swelling, pain on the left side of the abdomen with dragging sensation and easy satey.
He also complained of tiredness/weakness, sudden episodes of fainting attacks and weight loss. Two
moths prior to presentation, he gave a two week history of haematuria for which he was treated in a private
clinic. There was no history of bone pains, fever, night sweats or bleeding dissalise.
Physical examination revealed a chronically ill-looking elderly man. He was conscious and alert. He
had hemorphy several years ago otherwise his personal and family history was unremarkable.
severely pale, anicteric with generalizes lymphadenopathy (1cm). There was massive
splenomegaly (24cm midefavalure line), hepatomegaly (6cm) and moderate ascites. We suspected differential
cause of massive splenomegaly. Laboratory evaluation revealed the following results:
haemoglobin (Hb) 10g/dl, white blood cell count (WBC) 2.6 *10^9 /l with differentials of 35%
neutrophils, 65% lymphocytes, platelet count 90 *10^9 /l and ESR 130 mm/hr. Coombs direct and indirect
antiglobulin test and retroviral test were negative. The peripheral blood film showed hypochromia,
microcytosis, target and pencil shaped cells with no rouleux formation. There was normal morphology
but apparent reduction in granulocytes and platelets. A Perl's stain done was negative. Bone marrow cytology
revealed a hypercellular marrow and few megaloblasts. Plasma cytosis (12%) evenly dispersed
throughout the marrow was seen. Some of theses plasma cells were binucleated with inconspicuous
nucleoli. A few others showed accumulation of prominent cytoplasmic vacuoles. Bone marrow
histology confirmed mild plasma cytosis. A comprehensive myeloma work-up was initiated. Total
skeletal survey with chest thoracolumbar, pelvic x-ray were all normal. There was a slight reduction of
normal circulating immunoglobulin on serum protein electrophoresis. Urine analysis and urinary Bence
jones protein (BJP) was normal. Serum calcium was 8.0mg/dl, creatinine 1.5mg/dl, urea 25mg/dl,Hco3
20mmol/l and fasting blood sugar was 49mg/dl. No evidence of systemic myelomatosis was detected. An
abdominal ultrasound scan confirmed hepatosplenomegaly with spleen containing kidney showed multiple cysts (the largest measuring 12.4cm
*9.6cm). Supportive measures were instituted: two
units of packed erythrocyte transfusion was given over 2
day period, intravenous perfluorine 200mg 12hrly
for 10 days, haematinics and adequate fluid hydration.
Post transfusion Hct was 0.361/1, WBC 3.0 × 10^7/l and platelet count was 100 × 10^9/l. Following the atypical/ unusual clinical presentation of massive splenomegaly, reduced performance status with a previous history of haematuria and lack of typical features of MM (renal failure, hypercalcemia and bone pain), polychemotherapy could not be instituted. Ten days later he was commenced on a 4-day pulse of high-dose dexamethasone 12mg 8hrly/day 500 ml of 5% dextrose/water, and 40mg/d po on 15-18 every 4 weeks. The patient’s condition improved gradually and he was discharged 28 days after admission. Laboratory features at discharge showed Hb 12.5/dl, WBC 3.7 × 10^9/l, platelets 115 × 10^9/l and clinically spleen had decreased to 19cm. Therapy was maintained as described above and the patient was given a monthly clinic appointment. 3 months later on routine clinic visit, the spleen had decreased to 10cm, liver was nonpalpable and patient was remission with Hb 12.0/g/dl, WBC 4.0 × 10^9/l, platelets 120 × 10^9/l, and a repeat bone marrow revealed 6% plasma cells.

**DISCUSSION**

The diagnosis of smoldering myeloma (SM) is challenging and early identification of the disease is crucial as treatment is controversial in regards to obtaining remission. In this case report, the clinical presentation was unusual as patient presented with features of SM associated with a huge abdominal tumor involving the spleen, liver and left kidney. A similar case report of indolent myeloma in a 62-year-old woman who was under observation for 6 years period also developed a huge abdominal tumor. This imply subtype in terms of the natural history of MM.

Treatment is generally unsatisfactory in patients with SM who have a low tumor mass and slow disease progression. This is because those at risk for early or late disease progression could not be distinguished in order to prevent complications. They are often observed for a period of time before therapy is instituted. In advance economy, improvement in diagnostic techniques such as MR1, CT scan have resulted in early diagnosis and prompt treatment. In resources poor economy like ours, it is likely we may be seeing only symptomatic cases for a long time to come. Therefore, the “watch and wait” approach may not be feasible in our environment for now. The conclusion of dimopoulos et al is therefore applicable at present where the extent of disease at diagnosis and the subsequent rate of disease evolution are considered major factors in the total survival time.

We felt compelled to treat this patient with a nonchemotherapeutic agent because of the evidence of mild bone marrow plasmocytosis, massive splenomegaly including lymphadenopathy in the absence of active features of MM as manifested by CRAB. In addition, a long-term follow up of SM case in a recent study revealed that 25% of patients who received alkylating agents developed myelodysplastic syndrome (MDS) or acute leukemia. Also, chemotherapy is known to be effective in reducing bone pains and local radiotherapy for localized bone resistant to chemotherapy. Hence, the more active approach with the use of nonchemotherapy agents in selected patients and use of bisphosphonates in patients with or to prevent bone lesions or osteoporosis. Our patient was given high-dose dexamethasone. The use of dexamethasone is known to reduce tumor burden in selected patients who do not yet have overt MM or who are not candidates for chemotherapy. Also, the rate and extent of fall in paraprotein concentration can be increased by using high-dose which produces impressive serological response. The role of dexamethasone has also been recently established and more research are still ongoing in multicentre randomized trials (iFM 95-01) on the use of only dexamethasone. Initiating dexamethasone promptly to prevent paraplegia have also been found to be critical in the management of these patients. Our patient showed a remarkably improvement within the first few months of therapy with dexamethasone as the haematological parameters increase and there was clinical improvement.

We conclude that high-dose of dexamethasone is useful in case of SM in the elderly particularly those with unusual presentation of multiple symptomatic features. It is an effective, well-tolerated treatment protocol for patients who do not yet require chemotherapy.

**REFERENCES**


Smoldering/indolent myelom. C.E. Omoti.


